Brain function, quantified.

Precision biomarkers of brain function -
Accurate, reliable, and built for scale.

Measuring what matters most

For decades, neurology has chased a bold vision for quantifying brain function: measurements that are objective, direct, and accurate enough to detect meaningful change.

NeuraLight's precision biomarkers deliver on that vision - quantifying performance of visual tasks that engage distinct neural pathways, through one of the most direct windows into brain function known to science: the eyes.

From function to biomarkers

NeuraLight's software-based platform pairs visual tasks designed to engage specific brain functions with pioneering AI - translating performance into objective, quantitative measures of targeted brain regions.

01
ASSESSMENT
A short assessment completed in minutes, standardized across sites, languages, and workflows.
02
Analysis
Proprietary computer vision and machine learning algorithms capture and analyze task performance.
03
Results
Multiple biomarkers are extracted per assessment, quantifying various aspects of brain function.

Built at the intersection of neurology and technology.

A team spanning world-renowned neurologists, Nobel Laureates, and award-winning technologists. Built on the conviction that brain function can be made accurately measurable.

View All Team
Edmund Ben Ami
Co-Founder and CEO

Award-winning mathematician and repeat entrepreneur with 20+ years of experience building cutting-edge technologies in AI, computer vision, and signal processing.

Edmund Ben Ami
Co-Founder and CEO

Eddy is a repeat entrepreneur and an award-winning mathematician, with over 20 years of experience designing novel AI algorithms and building world-class teams to take on some of the most challenging technological challenges in signal processing, computer vision, and AI.

Gil Shklarski, PhD
Scientific Co-Founder

World-renowned technologist and scientific computing PhD. Served as CTO for Thirty Madison and Flatiron Health, leading the latter through its $2B acquisition by Roche.

Gil Shklarski, PhD
Scientific Co-Founder

Gil is a world-renowned technologist and scientific computing PhD who previously served as CTO of Thirty Madison and Flatiron Health (acquired by Roche for $2B) growing the technology team from two engineers to a team of over 350 across software, DevOps, IT, security, product design, and data science. At NeuraLight he is responsible for all cross-functional scaling and growth, and is also an avid startup investor, advisor and mentor.

Thomas C. Südhof, MD, PhD
Scientific Co-Founder

Nobel Laureate and pioneering neuroscientist recognized for his groundbreaking work on synaptic transmission. A leading Alzheimer's disease expert and head of The Südhof Lab at Stanford University.

Thomas C. Südhof, MD, PhD
Scientific Co-Founder

Prof. Südhof is a world-renowned neuroscientist who won a Nobel prize for his work on synaptic transmission. Currently heading the Südhof lab at Stanford, he’s considered by many one of the world’s leading researchers of Alzheimer’s Disease.

He has published over 500 scientific papers and is widely recognized for identifying key synaptic proteins such as synaptotagmins and neurexins. In addition to the Nobel Prize, he has received numerous honors, including the Lasker Award and the Kavli Prize, for his contributions to neuroscience.

Olivier Rascol, MD, PhD
Head of SAB

World-renowned neurologist and clinical pharmacologist specializing in movement disorders. Co-developer of the gold-standard Parkinson's disease measurement scale. Chair of the F-CRIN platform.

Olivier Rascol, MD, PhD
Head of SAB

Prof. Rascol is a world-renowned neurologist and clinical pharmacologist, an expert in Parkinson’s disease and movement disorders. Prof. Rascol has served as the secretary of the International Parkinson & Movement Disorders Society and as the Chair of its European section. He is either serving or has previously served as associate editor for the Movement Disorder Journal, the Journal of Neural Transmission and as a member of the editorial board of Lancet Neurology, Neurology, CNS Drugs and the European Journal of Neurology, and  has published more than 500 articles in international scientific journals.

Peer-reviewed publications